Clinical Trials Logo

Advanced Solid Malignant Tumors clinical trials

View clinical trials related to Advanced Solid Malignant Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT02690337 Completed - Clinical trials for Advanced Solid Malignant Tumors

Study of DS-1123a in Advanced Solid Tumours

Start date: January 2016
Phase: Phase 1
Study type: Interventional

This is an open-label study to evaluate the safety, tolerability, and pharmacokinetics of DS-1123a in Japanese subjects with advanced solid tumors.

NCT ID: NCT02675491 Completed - Clinical trials for Advanced Solid Malignant Tumors

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Start date: February 2016
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of DS-6051b in Japanese subjects with advanced solid malignant tumors harboring either a ROS1 or NTRK fusion gene.

NCT ID: NCT02192567 Terminated - Clinical trials for Advanced Solid Malignant Tumors

Open Label Study of DS-5573a

Start date: September 2014
Phase: Phase 1
Study type: Interventional

This is an open-label, sequential dose escalation and expansion study to evaluate the safety, and pharmacokinetics of DS-5573a in Japanese patients with advanced solid malignant tumors.

NCT ID: NCT01290471 Completed - Clinical trials for Advanced Ovarian Cancer

Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open label study to assess the safety and tolerability of U3 1565, determine maximum tolerated dose (MTD) or establish maximum administered dose (MAD) safety and tolerability.

NCT ID: NCT00503711 Completed - Clinical trials for Advanced Solid, Malignant Tumors

Phase I Chinese PK

Start date: September 2006
Phase: Phase 1
Study type: Interventional

An open, phase 1 to assess the PK of rising doses of ZD6474 when administered daily in Chinese patients with advanced solid malignant tumors.